Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors MedImmune

    • Most Recent Events

    • 27 Mar 2024 According to Brainomix media release, the company formed research collaboration with AstraZeneca to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients. The patient data from the trial was processed with Brainomix's e-Lung tool.
    • 08 Aug 2017 Primary endpoint has not been met (Change from Baseline in Percent-Predicted Forced Vital Capacity at Week 52), according to results published in the American Journal of Respiratory and Critical Care Medicine.
    • 08 Aug 2017 Results assessing efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis published in the American Journal of Respiratory and Critical Care Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top